![Haru Morita](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Haru Morita
Directeur Général chez
MODALIS THERAPEUTICS CORPORATION
Fortune : 923 744 $ au 31/10/2026
Profil
Mr. Haru Morita is a Chief Executive Officer at Modalis Therapeutics, Inc. and a Chief Executive Officer & Representative Director at Modalis Therapeutics Corp.
He is on the Board of Directors at Modalis Therapeutics Corp.
Mr. Morita was previously employed as a Chairman, President & Chief Executive Officer by REGiMMUNE Corp., a Principal by Booz Allen Hamilton International (U.K.) Ltd., a Research Scientist by Kirin Brewery Co. Ltd., and a Director-Business Development by Y's Therapeutics, Inc. He received his undergraduate degree from School of Engineering, The University of Tokyo and a graduate degree from School of Engineering, The University of Tokyo.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 27/05/2026 | 5 195 700 ( 4,57 % ) | 923 744 $ | 31/10/2026 |
Postes actifs de Haru Morita
| Sociétés | Poste | Début |
|---|---|---|
| MODALIS THERAPEUTICS CORPORATION | Directeur Général | 01/01/2016 |
Modalis Therapeutics, Inc.
 Modalis Therapeutics, Inc. Aerospace & DefenseElectronic Technology Part of Modalis Therapeutics Corp., Modalis Therapeutics, Inc. is an American biotechnology company specializing in gene therapies for rare genetic diseases. The company is located in the US. The company develops treatments using its proprietary CRISPR-GNDM® platform, an epigenome editing technology that modulates gene regulatory regions to correct gene regulation errors without altering DNA sequences. Its approach targets severe disorders affecting muscles, the heart, and the central nervous system. Modalis employs a hybrid business model that combines in-house drug development with collaborative partnerships, advancing candidates through discovery and early clinical stages before licensing manufacturing and commercialization rights. The company focuses on diseases with high unmet medical needs, including muscular dystrophies, cardiomyopathies, neurodegenerative diseases, and severe pediatric epilepsy, and its pipeline includes gene therapy candidates for conditions such as LAMA2-related congenital muscular dystrophy, Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, dilated cardiomyopathy, tauopathies, Angelman syndrome, and Dravet syndrome. Modalis utilizes muscle-specific viral vectors and delivery technologies to enhance targeting and safety, and actively seeks partnerships to expand and optimize its therapeutic pipeline. Haru Morita has been the CEO of the company since 2016. | Directeur Général | 01/04/2016 |
Anciens postes connus de Haru Morita
| Sociétés | Poste | Fin |
|---|---|---|
Booz Allen Hamilton International (U.K.) Ltd.
 Booz Allen Hamilton International (U.K.) Ltd. Miscellaneous Commercial ServicesCommercial Services Provides management and technology consulting services | Corporate Officer/Principal | - |
Kirin Brewery Co. Ltd.
 Kirin Brewery Co. Ltd. Beverages: AlcoholicConsumer Non-Durables Manufactures beer | Directeur Technique/Scientifique/R&D | - |
Y's Therapeutics, Inc.
 Y's Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceuticals | Corporate Officer/Principal | - |
REGiMMUNE Corp.
 REGiMMUNE Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops immune medicines | Directeur Général | - |
Formation de Haru Morita
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
7
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Y's Therapeutics, Inc.
Y's Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceuticals | Health Technology |
Kirin Brewery Co. Ltd.
Kirin Brewery Co. Ltd. Beverages: AlcoholicConsumer Non-Durables Manufactures beer | Consumer Non-Durables |
REGiMMUNE Corp.
REGiMMUNE Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops immune medicines | Health Technology |
Booz Allen Hamilton International (U.K.) Ltd.
Booz Allen Hamilton International (U.K.) Ltd. Miscellaneous Commercial ServicesCommercial Services Provides management and technology consulting services | Commercial Services |
School of Engineering, The University of Tokyo
 School of Engineering, The University of Tokyo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Modalis Therapeutics Corp.
 Modalis Therapeutics Corp. BiotechnologyHealth Technology Develops transformative therapeutics for diseases which are caused by malfunctioning of genes | Health Technology |
Modalis Therapeutics, Inc.
Modalis Therapeutics, Inc. Aerospace & DefenseElectronic Technology Part of Modalis Therapeutics Corp., Modalis Therapeutics, Inc. is an American biotechnology company specializing in gene therapies for rare genetic diseases. The company is located in the US. The company develops treatments using its proprietary CRISPR-GNDM® platform, an epigenome editing technology that modulates gene regulatory regions to correct gene regulation errors without altering DNA sequences. Its approach targets severe disorders affecting muscles, the heart, and the central nervous system. Modalis employs a hybrid business model that combines in-house drug development with collaborative partnerships, advancing candidates through discovery and early clinical stages before licensing manufacturing and commercialization rights. The company focuses on diseases with high unmet medical needs, including muscular dystrophies, cardiomyopathies, neurodegenerative diseases, and severe pediatric epilepsy, and its pipeline includes gene therapy candidates for conditions such as LAMA2-related congenital muscular dystrophy, Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, dilated cardiomyopathy, tauopathies, Angelman syndrome, and Dravet syndrome. Modalis utilizes muscle-specific viral vectors and delivery technologies to enhance targeting and safety, and actively seeks partnerships to expand and optimize its therapeutic pipeline. Haru Morita has been the CEO of the company since 2016. | Electronic Technology |
